Clinical Trial Detail

NCT ID NCT04060342
Title GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Indications

pancreatic adenocarcinoma

prostate cancer

gastric adenocarcinoma

stomach cancer

colorectal cancer

gastroesophageal adenocarcinoma

pancreatic cancer

esophagus adenocarcinoma

triple-receptor negative breast cancer

esophagus squamous cell carcinoma

colorectal adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

GB1275

GB1275 + Pembrolizumab

GB1275 + Gemcitabine + Nab-paclitaxel

Age Groups: adult senior

No variant requirements are available.